CAS: 24284-84-2; 17α-Cyanomethyl-1,3,5(10)-Estratriene-3,17-Diol 3-Methyl Ether
该化合物是Astradiol的合成衍生物,是一种自然产生的雌激素,该化合物具有雌激素的类固醇主干质特征,有特定的改变,包括位于17beta位置的氢氧基组和位于3位置的甲氧基组,这影响其生物活动和受体结合的亲和性.乙酰胺组的存在会增加其溶性,并可能影响其药理动力特性.通常会研究这些化合物在激素替代疗法,避孕配方或内分泌学研究工具中的潜在应用.结构改变可能导致雌激素受体的能量和选择性变化,使其在定向疗法的研制过程中具有价值.同许多类固醇衍生物一样,化合物的稳定性,溶性和再活性对于实验室和临床环境中的应用都至关重要.
- 英文名称17α-Cyanomethyl-1,3,5(10)-Estratriene-3,17-Diol 3-Methyl Ether
- 中文名称(17a)-17-羟基-3-甲氧基-19-去甲孕甾-1,3,5(10)-三烯-21-腈
- 其它别名19-Nor-17a-pregna-1,3,5(10)-triene-21-nitrile,17-hydroxy-3-methoxy- (8CI); 17a-Cyanomethylestradiol 3-methyl ether; STS 64
- CAS编号24284-84-2
- FDA UNII编号:8U5T7SU8VW
- 分子式:C21H27NO2分子量:325.44
- 产品CID: 1189484
- 产品分类分析化学 → 标准品 → 药典标准品和杂质标准品
物理性质
MSDS等安全信息
上下游产品
17α-Cyanomethyl-17β-hydroxyestr-4-en-3-one Dienogest estrone 3-methyl ether acetonitrile合成工艺路线路线简述
- 合成目标产物 Sts 64 主要起始原料 Estrone 3-Methyl Ether And Acetonitrile
- (文献来源)合成步骤主要原料 Estrone 3-Methyl Ether 和 Acetonitrile
📜3-甲氧基雌酮 以 四氢呋喃,水,丙酮,乙腈 用作溶剂,以78%的收率获得(17A)-17-羟基-3-甲氧基-19-去甲孕甾-1,3,5(10)-三烯-21-腈
参考文献:Process For The Production Of Unsaturated 17 .Alpha.-Cyanomethyl-17 .Beta.-
标题:Process For The Production Of Unsaturated 17 .Alpha.-Cyanomethyl-17 .Beta.-
摘要:公式i的不饱和17α-氰甲基-17β-羟基类固醇,其中r.Sub.1 =me,Eth; R.Sub.2 =h,Me; R.Sub.3 =h,Oh,一个乙酰氧基或烷氧基; R.Sub.4 =h,R.Sub.5 =oh,一个乙酰氧基,烷氧基,R.Sub.4和r.Sub.5一起代表一个酮基或缩醛基团,双键位于类固醇的基本结构中,特别是在类固醇环的15和16位置之间,从通式ii所述的不饱和17-酮类固醇中得到,通过将不饱和17-酮类固醇与lich.Sub.2 Cn反应,然后水解.公式i的化合物是药理学上有趣的类固醇化合物,也是用于合成高效类固醇产品的中间体,可用于人类和兽医学中治疗内分泌失调和生殖控制,基于它们特定的激素/抗激素作用.这些化合物适用于子宫内膜异位症的治疗,也可与乙烯雌二醇制剂结合用于生育控制.
海关参考信息
- 2902600000-乙苯
2902700000-异丙基苯
2905122000-异丙醇
2905143000-叔丁醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-5438134-A
优先权日:1990-07-09
标 题:Process for the production of unsaturated 17 α-cyanomethyl-17 β-h
发明人：TEICHMUELLER GERHARD; MUELLER GERD
权利人:JENAPHARM GMBH
摘要:The unsaturated 17α-cyanomethyl-17β-hydroxy steroids of the formula I, ##STR1## in which R 1 =Me, Eth; R 2 =H, Me; R 3 =H, OH, an acetoxy or alkoxy group; R 4 =H, R 5 =OH, an acetoxy, alkoxy group of R 4 and R 5 together represent a keto- or ketal group and double bonds are contained in the basic structure of the steroid, particularly between the 15 and 16 position in the steroid ring, from unsaturated 17-ketosteroids of the general formula II as described herein with the aforementioned meanings of R 1 to R 5 by reacting the unsaturated 17-ketosteroids with LiCH 2 CN and subsequently hydrolyzing. n The compounds of formula I are pharmacologically interesting steroid compounds or also intermediate products for the synthesis of highly-effective steroid products which can be used in human and veterinary medicine for the treatment of endocrine disorders and for reproductive control based on their specific hormonal/anti-hormonal actions. n The compounds are suitable for the treatment of endometriosis and also in combination with preparations with ethinylestradiol for fertility control.
